List of Excipients in Branded Drug CLINDAMYCIN HYDROCHLORIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Greenstone LLC	CLINDAMYCIN HYDROCHLORIDE	clindamycin hydrochloride	59762-3328	FD&C BLUE NO. 1
Greenstone LLC	CLINDAMYCIN HYDROCHLORIDE	clindamycin hydrochloride	59762-3328	FD&C YELLOW NO. 5
Greenstone LLC	CLINDAMYCIN HYDROCHLORIDE	clindamycin hydrochloride	59762-3328	GELATIN
Greenstone LLC	CLINDAMYCIN HYDROCHLORIDE	clindamycin hydrochloride	59762-3328	LACTOSE
Greenstone LLC	CLINDAMYCIN HYDROCHLORIDE	clindamycin hydrochloride	59762-3328	MAGNESIUM STEARATE
Greenstone LLC	CLINDAMYCIN HYDROCHLORIDE	clindamycin hydrochloride	59762-3328	STARCH, CORN
Greenstone LLC	CLINDAMYCIN HYDROCHLORIDE	clindamycin hydrochloride	59762-3328	TALC

Generic Drugs Containing CLINDAMYCIN HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Lannett Company Inc	clindamycin hydrochloride	0527-1381	ALCOHOL
Lannett Company Inc	clindamycin hydrochloride	0527-1381	AMMONIA
Lannett Company Inc	clindamycin hydrochloride	0527-1381	BUTYL ALCOHOL
Lannett Company Inc	clindamycin hydrochloride	0527-1381	D&C YELLOW NO. 10
Lannett Company Inc	clindamycin hydrochloride	0527-1381	FD&C GREEN NO. 3
Lannett Company Inc	clindamycin hydrochloride	0527-1381	GELATIN
Lannett Company Inc	clindamycin hydrochloride	0527-1381	ISOPROPYL ALCOHOL

What are the Most Frequently-Used Excipients in CLINDAMYCIN HYDROCHLORIDE?

# Of NDCs	Excipient
29	ALCOHOL
5	ALUMINUM OXIDE
44	AMMONIA
26	ANHYDROUS LACTOSE
1	BLUE 1
29	BUTYL ALCOHOL
1	CI 42090

Excipient Strategy and Commercial Opportunities for Clindamycin Hydrochloride

Last updated: February 26, 2026

What are the key excipient considerations for clindamycin hydrochloride formulations?

Clindamycin hydrochloride (HCl) is an antibiotic used for bacterial infections. As a pharmaceutical, its formulation depends on solid, topical, and injectable forms. Proper excipient selection ensures stability, bioavailability, and patient compliance.

Solid formulations (tablets and capsules)

• Binders and fillers: Microcrystalline cellulose, lactose, and dicalcium phosphate. These maintain tablet integrity.
• Disintegrants: Croscarmellose sodium, sodium starch glycolate. Facilitate uniform breakdown after ingestion.
• Lubricants: Magnesium stearate minimizes manufacturing issues.

Topical and injectable formulations

• Solvents: Water for injection, propylene glycol for solubility.
• Emulsifiers and stabilizers: Polysorbates, parabens.
• Preservatives: Methylparaben, phenol (for topical).

Excipient challenges

• Compatibility with the drug's stability profile.
• Minimizing immunogenic or allergic responses.
• Achieving consistent bioavailability.

How does excipient strategy impact manufacturing and marketability?

Effective excipient choice can reduce costs, improve shelf-life, and broaden formulations, creating opportunities for differentiation:

• Extended-release formulations: Utilizing specific polymers and binders (e.g., ethylcellulose) extend dosing intervals, appealing to patient compliance markets.
• Injectable stability: Formulations with antioxidants (e.g., sodium bisulfite) improve shelf-life.
• Topical applications: Using permeation enhancers (e.g., dimethyl sulfoxide) improves skin absorption, expanding indications.

What are the commercial implications of excipient customization?

• Patentability: Novel excipient combinations or delivery systems can secure patent protection, delaying generic competition.
• Market differentiation: Formulations with enhanced bioavailability, reduced dosing frequency, or better tolerability can command premium pricing.
• Regulatory pathways: Demonstrating excipient compatibility and stability facilitates faster approval, especially for proprietary formulations.

What are the main competitive opportunities?

Opportunity Type	Details	Potential Impact
Extended-release tablets	Using polymers like ethylcellulose	Increased adherence, premium pricing
Injectable formulations	Incorporating stabilizers, preservatives	Broader hospital use, reduced injections frequency
Topical products	Enhanced skin penetration	Expansion into acne, skin infections

What are the regulatory considerations?

• Excipient approval: Must be on approved lists or supported by safety data for intended routes.
• Compatibility testing: Demonstrates chemical stability.
• Labeling and documentation: Clear disclosure of excipients, especially for patient safety.

How can companies leverage excipient technology for growth?

• Invest in formulation R&D targeting new delivery systems.
• Develop proprietary excipient blends that improve pharmacokinetics.
• Explore combination products with synergistic excipients.

Summary of key opportunities

• Innovation in extended-release and injectable formulations offers market differentiation.
• Custom excipient combinations can create patent barriers.
• Regulatory strategy focusing on excipient safety and compatibility accelerates approval.
• Focused development efforts can unlock premium markets, especially for specialized patient populations.

Key Takeaways

1. excipient optimization is critical for formulation stability, bioavailability, and patient adherence.
2. Extended-release and injectable formulations represent significant growth domains.
3. Proprietary excipient systems provide competitive barriers and pricing advantages.
4. Regulatory compliance and safety data are essential for excipient approval.
5. Market opportunities exist across oral, topical, and injectable segments, driven by formulation innovation.

FAQs

Q1: What excipients are most common in clindamycin hydrochloride tablets?
Microcrystalline cellulose (filler), croscarmellose sodium (disintegrant), and magnesium stearate (lubricant) are typical.

Q2: Can excipient selection impact the drug’s stability?
Yes. Compatibility with clindamycin HCl is critical to prevent degradation and maintain potency.

Q3: What excipients are used in injectable formulations?
Water for injection as solvent, preservatives like methylparaben, and stabilizers such as sodium bisulfite are common.

Q4: How can excipient innovation extend market exclusivity?
Developing new delivery systems or combining proprietary excipients can qualify for patent protection.

Q5: What are regulatory challenges related to excipients?
Ensuring excipients meet safety standards and are compatible with the drug product for its intended route and duration.

---

References

[1] U.S. Food and Drug Administration (FDA). (2022). Inactive Ingredient Database. Retrieved from https://www.accessdata.fda.gov/scripts/iig/index.cfm